Q3 Revenue Up 10%, Adjusted EPS Jumps 53% as Bausch Health Raises Full-Year Guidance
BHC sits 60% above its 52-week low of $4.33 on elevated volume (2.2× avg).
Summary
Bausch Health beat on nearly every line for Q3 2026: consolidated revenue of $2.94 billion rose 10% reported and 8% organic, GAAP diluted EPS came in at $1.15 versus $0.48 a year ago, and adjusted EPS of $1.77 was up 53%. Adjusted EBITDA attributable to Bausch Health reached $1,305 million, up 32%, and the ex-Bausch + Lomb business topped $1 billion in quarterly Adjusted EBITDA for the first time — its fourteenth straight quarter of year-over-year revenue and EBITDA growth. Management raised full-year 2026 revenue, Adjusted EBITDA and Adjusted Cash Flows from Operations guidance for the ex-B+L business, and the board authorized a $50 million buyback aimed at offsetting dilution from 2027 equity vesting. Cash generation was the standout: $813 million from operations in the quarter versus $405 million a year ago, supporting more than $500 million of net debt reduction and lifting cash to $2,485 million from $1,309 million at year-end 2025. The company again flagged it is evaluating all options for unlocking shareholder value, including maximizing the Bausch Health and Bausch + Lomb assets. The 5:00 p.m. EDT call today is where guidance specifics and any separation commentary get tested.
At the time of this announcement, BHC was trading at $6.92 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $4.33 to $8.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.